Stephens & Co. Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.75
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Stephens & Co. analyst Jeff Garro maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $2 to $1.75.
Stephens & Co. analyst Jeff Garro maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $2 to $1.75.